Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Piramal to expand...

    Piramal to expand pharma vertical presence in US, Europe

    Written by Ruby Khatun Khatun Published On 2017-07-12T14:39:15+05:30  |  Updated On 12 July 2017 2:39 PM IST

    New Delhi: Piramal Enterprises has said it is looking to expand presence of its pharma vertical in global markets such as the US, Europe and Japan with plans to introduce more products going forward.


    North America and Europe account for over 70 per cent of the company's revenue from pharmaceuticals business.


    "Piramal will continue to add more generic hospital products both organically and inorganically to leverage its strong sales and distribution network, integrating acquired products and generating synergies," Piramal Enterprises said in its annual report for 2016-17.


    On geographical expansion, the reports said the company would "further expand presence in strong markets, including the US, Europe and Japan."


    Piramal's pharma vertical is divided into two --- the global pharma business that sells pharma products and services globally and the India consumer products business that sells OTC products in India.


    The company operates through its own field force in the US, the UK, Italy, and Germany and through more than 80 business partners in other countries. It has distribution presence in over 110 countries across the world.


    It has four plants in North America and two plants in the UK and has dedicated sales force in North America and Europe. In the US it has 30 per cent market share in inhalation anaesthesia.


    "Piramal continues to strengthen its distribution presence in key European countries like the UK, Italy, Germany, and others," the report added.


    Over the past six years, the company has cleared 28 USFDA audits, 78 other regulatory inspections and 568 customer inspections, the report said.


    In the current fiscal, the company plans to launch Desflurane, the latest generation of inhalation anaesthesia.

    anaesthesiaauditsDesfluraneEuropeexpandglobal pharma businessIndiainhalationJapanNorth AmericaOTCpharma verticalpharmaceuticals businessPiramalPiramal enterprisespresenceproductsUKUSUSFDA
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok